Adoptive-cell-transfer therapy for the treatment of patients with cancer

By M. Dudley, S. Rosenberg. Nature Reviews. Cancer, 2003

686 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity (2017, positive): “This poses a major limitation on their use for adoptive therapy, as in vivo persistence of effector cells are crucial for sustained clinical responses.(46) We therefore incorporated in our construct the gene encoding IL-15, a cytokine that drives NK cell expansion and persistence.”
Restoring function in exhausted CD8 T cells during chronic viral infection (2006, neutral): “Finally, our studies have implications for therapeutic vaccination and T-cell immunotherapy 26,27 .”
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. (2005, methodology): “Currently, the only criterion applied to selecting cells for adoptive transfer to patients with solid tumors is the ability of antitumor T cells to release IFN-γ and kill tumor cells upon coculture (2, 10).”